Pfizer Projects 2026 Revenue Guidance of $62 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 16 2025
0mins
Should l Buy PFE?
Source: Newsfilter
- Revenue Guidance Adjustment: Pfizer revised its 2025 revenue guidance to approximately $62 billion, up from a previous range of $61 to $64 billion, indicating confidence in future market performance despite challenges from declining COVID-19 product revenues.
- 2026 Revenue Outlook: The company anticipates 2026 revenues to range between $59.5 billion and $62.5 billion, reflecting an expected $1.5 billion decrease in COVID-19 product revenues and the negative impact of certain products losing exclusivity.
- R&D and Sales Expenses: Pfizer expects adjusted selling, general, and administrative expenses for 2026 to be between $12.5 billion and $13.5 billion, with R&D expenses projected between $10.5 billion and $11.5 billion, highlighting ongoing investments in key therapeutic areas and progress in its cost realignment program.
- Earnings Per Share Forecast: The adjusted diluted EPS for 2026 is projected to be between $2.80 and $3.00, primarily reflecting anticipated revenues and an expected increase in the effective tax rate, demonstrating the company's efforts to maintain profitability amidst changing market conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 26.860
Low
24.00
Averages
28.56
High
35.00
Current: 26.860
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer Faces Drug Pricing Pressure Amidst Market Challenges
- Attractive Dividend Yield: Pfizer's current dividend yield stands at 6.5%, which, despite ongoing drug pricing pressures, attracts investors seeking safe assets, potentially providing support for its stock price.
- Increasing Market Challenges: Pfizer has experienced a 57% decline in stock price post-COVID, and new U.S. government drug pricing policies may further impact its revenues, diminishing investor confidence in its future growth prospects.
- Acquisition and R&D Investment: In 2025, Pfizer invested over $10 billion in internal research and expanded its oncology portfolio through the acquisition of Seagen, actively seeking growth opportunities despite facing patent expirations.
- Long-term Dividend Growth Potential: While facing policy pressures in the short term, Pfizer has historically maintained dividend growth, and if it successfully enters the obesity drug market and expands its cancer drug portfolio, the potential for long-term dividend growth remains.
See More
U.S. Signs Trade Agreement with Ecuador to Lower Tariffs
- Tariff Reductions: The trade agreement signed by U.S. Trade Representative Jamieson Greer with Ecuador reduces tariffs across various industrial and agricultural sectors, potentially opening a market of 18 million consumers for U.S. exporters of machinery, IT, and chemicals, thereby enhancing U.S. trade standing in Latin America.
- Investment Roadmap: The agreement establishes a roadmap for investment in critical mineral projects, aligning with the Trump administration's strategy to diversify supply chains and reduce dependence on non-market economies, which could enhance U.S. competitiveness in global mineral resources.
- Immigration Control Measures: The pact includes significant national security and immigration provisions, requiring Ecuador to implement transit visas for
See More
Pfizer Faces Challenges but Remains an Attractive Investment
- Strong Profitability: Pfizer boasts a dividend yield of 6.5%, one of its highest ever, which continues to attract dividend investors despite a 57% drop from all-time highs, indicating a potential buying opportunity.
- Changing Market Dynamics: New U.S. government mandates aimed at lowering drug prices may lead to a revenue decline for Pfizer in 2026, altering the competitive landscape of the pharmaceutical industry and putting pressure on its stock price.
- Acquisition and R&D Investment: The acquisition of Seagen enhances Pfizer's oncology portfolio, and with over $10 billion allocated to internal research in 2025, the company demonstrates a strong commitment to drug development.
- Long-Term Growth Potential: Despite challenges from patent expirations, Pfizer has opportunities to sustain dividend growth by expanding its cancer drug portfolio and entering the obesity drug market, likely appealing to investors seeking safe assets.
See More
Adobe CEO Narayen to Step Down, Shares Drop 7%
- Leadership Transition: Adobe CEO Shantanu Narayen announced his intention to step down after a successor is appointed, while remaining as chair, which led to a 7% drop in shares during after-hours trading, indicating market unease regarding the leadership change.
- Strong Financial Results: Adobe's earnings report revealed an adjusted EPS of $6.06, surpassing the expected $5.87, with revenue hitting $6.40 billion, exceeding the $6.28 billion forecast, demonstrating robust profitability amid market challenges.
- AI Product Growth: The company reported that annualized revenue from AI-first products has more than tripled, highlighting Adobe's strategic positioning in the rapidly evolving AI sector, even as its stock has fallen nearly 23% in 2026 due to broader market concerns.
- Market Reaction: Despite subscription revenue from creative and marketing professionals reaching $4.39 billion, a 12% year-over-year increase, investor concerns over generative AI models have led to a punitive response, with Adobe's stock down over 60% from its 2021 peak.
See More
Adobe CEO Shantanu Narayen to Step Down Amid AI Concerns
- Leadership Transition: Adobe's CEO Shantanu Narayen will step down after a successor is named, while remaining as board chair, a move that may shake investor confidence given his successful leadership since 2007, during which Adobe transitioned from software licenses to a subscription model.
- Stock Price Decline: Adobe's shares have fallen 23% this year, driven by concerns over the impact of artificial intelligence, with a 6% drop in after-hours trading reflecting overall market pessimism in the software sector, potentially affecting the company's financing capabilities and competitive position.
- Strong Financial Performance: Adobe reported adjusted earnings per share of $6.06, exceeding the expected $5.87, with revenue of $6.40 billion also surpassing the $6.28 billion forecast, indicating the company's ability to maintain growth amidst market challenges, particularly with a 12% increase in subscription revenue from creative and marketing professionals.
- Future Guidance: Adobe's guidance for the next fiscal quarter suggests adjusted earnings per share between $5.80 and $5.85, with revenue projected at $6.43 billion to $6.48 billion, slightly above analyst expectations, indicating the company's ongoing investment in generative AI while striving to maintain profitability.
See More
Pfizer Stock Shows Signs of Reversal Potential
- Technical Reversal Signals: Pfizer's stock has formed a series of higher lows over the past year, breaking above its downtrend since the 2024 peak, indicating potential for a reversal that may provide investors with a timely re-entry opportunity.
- Defined Support Levels: The stock's downside support is clearly defined around the rising 50-day moving average, forming an ascending triangle with a breakout target of $30.50, suggesting a favorable risk/reward scenario in the current market environment.
- Improving Momentum Indicators: The Relative Strength Index (RSI) is trending higher and not overbought, indicating enhanced buying momentum, allowing investors to consider buying on recent weakness to capitalize on a potential rally above $27.50 towards $30.
- Safe Dividend Yield: With a current dividend yield of 6.4%, Pfizer, as part of the large pharma sector, may serve as a safe haven for investors amid increasing market volatility, providing stable returns with relatively low risk.
See More
Pfizer Faces Drug Pricing Pressure Amidst Market Challenges
- Attractive Dividend Yield: Pfizer's current dividend yield stands at 6.5%, which, despite ongoing drug pricing pressures, attracts investors seeking safe assets, potentially providing support for its stock price.
- Increasing Market Challenges: Pfizer has experienced a 57% decline in stock price post-COVID, and new U.S. government drug pricing policies may further impact its revenues, diminishing investor confidence in its future growth prospects.
- Acquisition and R&D Investment: In 2025, Pfizer invested over $10 billion in internal research and expanded its oncology portfolio through the acquisition of Seagen, actively seeking growth opportunities despite facing patent expirations.
- Long-term Dividend Growth Potential: While facing policy pressures in the short term, Pfizer has historically maintained dividend growth, and if it successfully enters the obesity drug market and expands its cancer drug portfolio, the potential for long-term dividend growth remains.
See More
U.S. Signs Trade Agreement with Ecuador to Lower Tariffs
- Tariff Reductions: The trade agreement signed by U.S. Trade Representative Jamieson Greer with Ecuador reduces tariffs across various industrial and agricultural sectors, potentially opening a market of 18 million consumers for U.S. exporters of machinery, IT, and chemicals, thereby enhancing U.S. trade standing in Latin America.
- Investment Roadmap: The agreement establishes a roadmap for investment in critical mineral projects, aligning with the Trump administration's strategy to diversify supply chains and reduce dependence on non-market economies, which could enhance U.S. competitiveness in global mineral resources.
- Immigration Control Measures: The pact includes significant national security and immigration provisions, requiring Ecuador to implement transit visas for
See More
Pfizer Faces Challenges but Remains an Attractive Investment
- Strong Profitability: Pfizer boasts a dividend yield of 6.5%, one of its highest ever, which continues to attract dividend investors despite a 57% drop from all-time highs, indicating a potential buying opportunity.
- Changing Market Dynamics: New U.S. government mandates aimed at lowering drug prices may lead to a revenue decline for Pfizer in 2026, altering the competitive landscape of the pharmaceutical industry and putting pressure on its stock price.
- Acquisition and R&D Investment: The acquisition of Seagen enhances Pfizer's oncology portfolio, and with over $10 billion allocated to internal research in 2025, the company demonstrates a strong commitment to drug development.
- Long-Term Growth Potential: Despite challenges from patent expirations, Pfizer has opportunities to sustain dividend growth by expanding its cancer drug portfolio and entering the obesity drug market, likely appealing to investors seeking safe assets.
See More
Adobe CEO Narayen to Step Down, Shares Drop 7%
- Leadership Transition: Adobe CEO Shantanu Narayen announced his intention to step down after a successor is appointed, while remaining as chair, which led to a 7% drop in shares during after-hours trading, indicating market unease regarding the leadership change.
- Strong Financial Results: Adobe's earnings report revealed an adjusted EPS of $6.06, surpassing the expected $5.87, with revenue hitting $6.40 billion, exceeding the $6.28 billion forecast, demonstrating robust profitability amid market challenges.
- AI Product Growth: The company reported that annualized revenue from AI-first products has more than tripled, highlighting Adobe's strategic positioning in the rapidly evolving AI sector, even as its stock has fallen nearly 23% in 2026 due to broader market concerns.
- Market Reaction: Despite subscription revenue from creative and marketing professionals reaching $4.39 billion, a 12% year-over-year increase, investor concerns over generative AI models have led to a punitive response, with Adobe's stock down over 60% from its 2021 peak.
See More
Adobe CEO Shantanu Narayen to Step Down Amid AI Concerns
- Leadership Transition: Adobe's CEO Shantanu Narayen will step down after a successor is named, while remaining as board chair, a move that may shake investor confidence given his successful leadership since 2007, during which Adobe transitioned from software licenses to a subscription model.
- Stock Price Decline: Adobe's shares have fallen 23% this year, driven by concerns over the impact of artificial intelligence, with a 6% drop in after-hours trading reflecting overall market pessimism in the software sector, potentially affecting the company's financing capabilities and competitive position.
- Strong Financial Performance: Adobe reported adjusted earnings per share of $6.06, exceeding the expected $5.87, with revenue of $6.40 billion also surpassing the $6.28 billion forecast, indicating the company's ability to maintain growth amidst market challenges, particularly with a 12% increase in subscription revenue from creative and marketing professionals.
- Future Guidance: Adobe's guidance for the next fiscal quarter suggests adjusted earnings per share between $5.80 and $5.85, with revenue projected at $6.43 billion to $6.48 billion, slightly above analyst expectations, indicating the company's ongoing investment in generative AI while striving to maintain profitability.
See More
Pfizer Stock Shows Signs of Reversal Potential
- Technical Reversal Signals: Pfizer's stock has formed a series of higher lows over the past year, breaking above its downtrend since the 2024 peak, indicating potential for a reversal that may provide investors with a timely re-entry opportunity.
- Defined Support Levels: The stock's downside support is clearly defined around the rising 50-day moving average, forming an ascending triangle with a breakout target of $30.50, suggesting a favorable risk/reward scenario in the current market environment.
- Improving Momentum Indicators: The Relative Strength Index (RSI) is trending higher and not overbought, indicating enhanced buying momentum, allowing investors to consider buying on recent weakness to capitalize on a potential rally above $27.50 towards $30.
- Safe Dividend Yield: With a current dividend yield of 6.4%, Pfizer, as part of the large pharma sector, may serve as a safe haven for investors amid increasing market volatility, providing stable returns with relatively low risk.
See More
